V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003466 | 210013461 | 1.71 | 116.2 | Neo-adjuvant (N) | 2021-11-01 | 2021-12-03 | null | 02 | N | TRIAL UNSPECIFIED | 100042368 |
| 210003473 | 210013462 | 1.59 | 55.2 | null | null | 2021-05-11 | Fulvestrant + Palbociclib | 02 | null | DOCETAXEL + TRASTUZUMAB | 100851270 |
| 210003521 | 210013464 | 1.66 | 51.45 | Neo-adjuvant (N) | null | 2019-04-01 | null | 01 | N | NAB-PACLITAXEL | 100132424 |
| 210003700 | 210013466 | 1.96 | 74.25 | Curative (C) | null | 2018-08-31 | Capecitabine | 02 | N | CAPECITABINE | 100539097 |
| 210003879 | 210013468 | 1.66 | 53.2 | null | null | 2021-09-03 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100017528 |
| 210003568 | 210013471 | null | null | Adjuvant (A) | 2022-03-13 | 2022-03-20 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100026134 |
| 210003608 | 210013565 | 1.72 | 54.1 | Adjuvant (A) | 2021-03-25 | 2021-08-17 | TRASTUZUMAB | null | N | TRASTUZUMAB | 101459971 |
| 210003610 | 210013566 | 1.54 | 93 | Adjuvant (A) | 2020-05-17 | 2020-05-31 | PACLITAXEL | null | N | PACLITAXEL | 101694091 |
| 210003614 | 210013567 | 1.68 | 123.8 | Palliative (P) | 2021-02-27 | 2021-03-31 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100051436 |
| 210003622 | 210013568 | null | null | null | 2018-11-23 | 2019-01-30 | Paclitaxel 7 day | 02 | null | PACLITAXEL | 100628901 |
| 210003629 | 210013570 | 1.56 | 79.8 | Curative (C) | 2018-11-14 | 2019-02-27 | Docetaxel | null | N | DOCETAXEL | 101399238 |
| 210003633 | 210013571 | 1.69 | 67 | Neo-adjuvant (N) | 2017-11-26 | 2017-12-11 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100306543 |
| 210003634 | 210013572 | 1.61 | 55.7 | Palliative (P) | null | 2018-07-20 | Docetaxel | 02 | null | DOCETAXEL | 101537298 |
| 210003635 | 210013573 | 1.62 | 110.7 | Adjuvant (A) | 2021-09-22 | 2021-10-07 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 101110095 |
| 210003637 | 210013574 | 1.69 | 68.7 | Adjuvant (A) | null | 2021-09-12 | Docetaxel | 02 | N | DOCETAXEL | 100715250 |
| 210003645 | 210013578 | 1.5 | 72.2 | Palliative (P) | null | 2021-06-19 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100213240 |
| 210003648 | 210013580 | 1.69 | 105.7 | null | 2021-09-21 | 2021-12-09 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100213352 |
| 210003662 | 210013582 | 1.5 | null | Palliative (P) | 2018-07-20 | 2018-10-28 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100138986 |
| 210003667 | 210013583 | 1.51 | 85.8 | null | 2021-03-14 | 2021-06-16 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100691223 |
| 210003675 | 210013585 | 1.56 | 72 | Adjuvant (A) | null | 2017-06-17 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100967742 |
| 210003679 | 210013587 | null | 98.5 | null | 2019-10-26 | 2020-02-08 | Docetaxel | null | null | DOCETAXEL | 101863233 |
| 210003686 | 210013588 | null | 60 | Adjuvant (A) | 2021-01-30 | 2021-02-27 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101457830 |
| 210003689 | 210013589 | null | 0 | null | 2021-02-17 | 2021-05-07 | Docetaxel | null | null | DOCETAXEL | 101857012 |
| 210003690 | 210013590 | null | 45 | Palliative (P) | 2021-11-08 | 2022-04-28 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 100856400 |
| 210003691 | 210013591 | 1.61 | 94.7 | null | null | 2019-05-03 | Trastuzumab 21 day loading dose | 02 | N | TRASTUZUMAB | 100478792 |
| 210003712 | 210013594 | 1.76 | 105.6 | Adjuvant (A) | 2020-06-06 | 2020-10-21 | Trastuzumab | null | N | TRASTUZUMAB | 101840371 |
| 210003719 | 210013597 | 1.65 | 80 | Palliative (P) | null | 2019-10-24 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101426308 |
| 210003721 | 210013598 | null | 63 | null | 2020-05-13 | 2020-07-30 | Trastuzumab 21 day maintenance | 02 | null | TRASTUZUMAB | 100577965 |
| 210003722 | 210013599 | 1.61 | 43.7 | Adjuvant (A) | null | 2020-02-16 | Paclitaxel 7 day | null | N | PACLITAXEL | 100420307 |
| 210003723 | 210013600 | 1.68 | 74.3 | null | null | 2020-04-02 | Trastuzumab | 02 | N | TRASTUZUMAB | 100832036 |
| 210003727 | 210013602 | 1.53 | 112.8 | Palliative (P) | null | 2018-11-14 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101141121 |
| 210003728 | 210013603 | 1.73 | 0 | Adjuvant (A) | null | 2019-01-19 | Paclitaxel 7 day | null | N | PACLITAXEL | 100605706 |
| 210003729 | 210013604 | 1.55 | 0 | Palliative (P) | 2020-05-21 | 2020-07-12 | PACLITAXEL | 02 | N | PACLITAXEL | 100347717 |
| 210003736 | 210013605 | null | 91 | null | null | 2019-12-25 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101855705 |
| 210003741 | 210013606 | 1.65 | 100 | null | null | 2021-08-18 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100738148 |
| 210003748 | 210013608 | 1.66 | 87.7 | Adjuvant (A) | null | 2017-09-09 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 101091256 |
| 210003749 | 210013609 | 1.57 | 119.9 | Palliative (P) | null | 2020-12-30 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 101397605 |
| 210003751 | 210013611 | 1.69 | 62.3 | Adjuvant (A) | 2021-03-28 | 2021-06-30 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101566613 |
| 210003753 | 210013612 | 1.69 | 59 | Neo-adjuvant (N) | 2021-12-11 | 2022-01-08 | Trastuzumab | null | N | TRASTUZUMAB | 100556658 |
| 210003754 | 210013613 | null | 55.2 | null | 2020-04-15 | 2020-05-08 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100575774 |
| 210003767 | 210013614 | 1.58 | 61.9 | Palliative (P) | 2020-11-16 | 2021-01-20 | CISPLATIN + ETOPOSIDE | null | N | CARBOPLATIN + PACLITAXEL | 100759298 |
| 210003768 | 210013615 | null | 54 | null | null | 2021-04-17 | null | null | null | FULVESTRANT + PALBOCICLIB | 101547987 |
| 210003792 | 210013619 | null | null | null | null | 2021-11-09 | Carboplatin + Docetaxel | 02 | null | DOCETAXEL + TRASTUZUMAB | 100133076 |
| 210003794 | 210013620 | 1.59 | 67.55 | Palliative (P) | 2020-05-17 | 2020-06-06 | null | 02 | N | EPIRUBICIN | 101774771 |
| 210003797 | 210013621 | 1.65 | 64.9 | Adjuvant (A) | 2022-02-01 | 2022-02-02 | Pertuzumab (Maintenance) | 02 | N | PERTUZUMAB | 100216251 |
| 210003803 | 210013622 | 1.61 | 57 | null | 2021-11-07 | 2021-11-25 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100784792 |
| 210003805 | 210013623 | 1.7 | 99.4 | Neo-adjuvant (N) | null | 2020-05-18 | Paclitaxel+Trastuzumab wkly Maint | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100072693 |
| 210003809 | 210013625 | 1.66 | null | Adjuvant (A) | 2021-02-02 | 2021-02-10 | Capecitabine | null | N | CAPECITABINE | 101688181 |
| 210003811 | 210013626 | 1.64 | 70.8 | Palliative (P) | 2022-04-23 | 2022-05-02 | ROSCO Trial | null | N | ROSCO TRIAL | 100844377 |
| 210003813 | 210013627 | 1.53 | 66.45 | Adjuvant (A) | 2021-09-20 | 2021-12-09 | FEC 100 | 02 | N | CYTARABINE + RITUXIMAB | 101270324 |